ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.797,26
-0,68%
S&P 500
5.305,58
-0,03%
US Dollar vs BRL
5,147
-0,11%
Bitcoin
67.785,64
-1,91%
Brent Oil
81,115
-0,51%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Corcept Therapeutics Inc (CORT)

  7. Corcept Therapeutics Inc (CORT) Notícias

CORT

Corcept Therapeutics (CORT)

Corcept Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CORT
DataHoraFonteTítuloCódigoCompanhia
21/05/202419:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CORTCorcept Therapeutics Inc
13/05/202413:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CORTCorcept Therapeutics Inc
01/05/202417:05GlobeNewswire Inc.Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateNASDAQ:CORTCorcept Therapeutics Inc
29/04/202409:00GlobeNewswire Inc.Corcept Completes Enrollment in Phase 4 CATALYST TrialNASDAQ:CORTCorcept Therapeutics Inc
24/04/202417:05GlobeNewswire Inc.Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallNASDAQ:CORTCorcept Therapeutics Inc
22/04/202409:00GlobeNewswire Inc.Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s SyndromeNASDAQ:CORTCorcept Therapeutics Inc
15/04/202409:00GlobeNewswire Inc.Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)NASDAQ:CORTCorcept Therapeutics Inc
08/04/202409:00GlobeNewswire Inc.Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian CancerNASDAQ:CORTCorcept Therapeutics Inc
01/04/202409:00GlobeNewswire Inc.Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s SyndromeNASDAQ:CORTCorcept Therapeutics Inc
15/02/202418:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CORTCorcept Therapeutics Inc
15/02/202418:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CORTCorcept Therapeutics Inc
15/02/202418:07GlobeNewswire Inc.Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate UpdateNASDAQ:CORTCorcept Therapeutics Inc
15/02/202418:02GlobeNewswire Inc.Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical TrialNASDAQ:CORTCorcept Therapeutics Inc
14/02/202418:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CORTCorcept Therapeutics Inc
13/02/202418:46Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:CORTCorcept Therapeutics Inc
08/02/202418:05GlobeNewswire Inc.Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference CallNASDAQ:CORTCorcept Therapeutics Inc
29/01/202410:00GlobeNewswire Inc.Corcept Appoints Roberto Vieira as President, OncologyNASDAQ:CORTCorcept Therapeutics Inc
08/01/202410:00GlobeNewswire Inc.Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase ProgramNASDAQ:CORTCorcept Therapeutics Inc
02/01/202410:00GlobeNewswire Inc.Court Finds Corcept Therapeutics’ Patents Not InfringedNASDAQ:CORTCorcept Therapeutics Inc
01/11/202317:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CORTCorcept Therapeutics Inc
01/11/202317:05GlobeNewswire Inc.Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:CORTCorcept Therapeutics Inc
01/11/202309:00GlobeNewswire Inc.Corcept Appoints Monica Tellado as President, Emerging MarketsNASDAQ:CORTCorcept Therapeutics Inc
26/10/202317:05GlobeNewswire Inc.Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)NASDAQ:CORTCorcept Therapeutics Inc
25/10/202317:05GlobeNewswire Inc.Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallNASDAQ:CORTCorcept Therapeutics Inc
15/08/202318:35Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:CORTCorcept Therapeutics Inc
02/08/202317:05GlobeNewswire Inc.Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:CORTCorcept Therapeutics Inc
26/07/202317:05GlobeNewswire Inc.Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference CallNASDAQ:CORTCorcept Therapeutics Inc
17/07/202317:05GlobeNewswire Inc.Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)NASDAQ:CORTCorcept Therapeutics Inc
27/06/202309:00GlobeNewswire Inc.Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian CancerNASDAQ:CORTCorcept Therapeutics Inc
16/06/202307:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CORTCorcept Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CORT

Seu Histórico Recente

BIT
P1W7M5
NLBNPIT1W7M5 20240621 90
USOTC
EDVGF
Endeavour (PK)
COIN
ESGGUST
Energy Solution Global
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados